Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the […]
Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and […]
Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]
Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech […]
With the rapid development of antibiotics in the 1930s, phage therapy – using viruses known as bacteriophages or phages to tackle bacterial infections – fell into oblivion. But as the current rise in antibiotic resistance […]
Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under […]
The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation […]
Following the announcement of Lallemand’s new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company’s goals and objectives. Can you elaborate on how the new laboratories […]
Professor Figeys is the founding Director of the School of Pharmaceutical Sciences and of the Ottawa Institute of Systems Biology, Faculty of Medicine, at the University of Ottawa in Canada. His research focuses on developing […]
EnteroBiotix Limited (‘EnteroBiotix’ or the ‘Company’), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced positive results from its Phase 1b IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis. EnteroBiotix’s […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced updated […]